KymaThera secures $80M Series B to advance oral PI3Kα inhibitor K-1728 as biotech peers raise funds and go public

KymaThera, a San Diego biotech, announced an $80 million Series B round to fund development of its pan-mutant selective PI3Kα inhibitor, K-1728.

The oral candidate is planned to enter Phase 1 clinical testing soon, aiming to target cancers driven by PI3Kα mutations.

The funding news came alongside other biotech financing activity, with Rouge also raising venture capital and Vaxcyte and Spyre completing public offerings, underscoring continued investor interest in the sector.